Ovarian response to 150 µg corifollitropin alfa in a GnRH-antagonist multiple-dose protocol: a prospective cohort study  Tamara Lerman, Marion Depenbusch,

Slides:



Advertisements
Similar presentations
E.H. Duran, D. Dowling-Lacey, S. Bocca, L. Stadtmauer, S. Oehninger 
Advertisements

Kay Neumann, Georg Griesinger  Reproductive BioMedicine Online 
Vuong Thi Ngoc Lan, Nguyen Khanh Linh, Ho Manh Tuong, P. C
Fresh and cryopreserved ovary transplantation and resting follicle recruitment  Sherman Silber, Jorge Pineda, Kathleen Lenahan, Michael DeRosa, Jeffrey.
J. C. Castillo, M. Dolz, E. Bienvenido, L. Abad, E. M. Casañ, F
Norbert Gleicher, Andrea Weghofer, David H. Barad 
J. C. Castillo, M. Dolz, E. Bienvenido, L. Abad, E. M. Casañ, F
External validation of nomogram for the decline in serum anti-Müllerian hormone in women: a population study of 15,834 infertility patients  Scott M.
Corifollitropin alfa doses based on body weight: clinical overview of drug exposure and ovarian response  William L. Ledger, Bart C.J.M. Fauser, Paul.
Can the fall in serum FSH during coasting in IVF/ICSI predict clinical outcomes?  Adrija Kumar Datta, Ariel Zosmer, Amanda Tozer, Luca Sabatini, Colin.
Effect of HCG-day serum progesterone and oestradiol concentrations on pregnancy outcomes in GnRH agonist cycles  Ze Wu, Rong Li, Yanping Ma, Bo Deng,
Follicular and endocrine response to anastrozole versus clomiphene citrate administered in follicular phase to normoovulatory women: a randomized comparison 
Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF  Bart C.J.M. Fauser, Michael.
Ovarian response markers lead to appropriate and effective use of corifollitropin alpha in assisted reproduction  Antonio La Marca, Giovanni D’Ippolito 
N. la Cour Freiesleben, T. A. Gerds, J. L. Forman, J. D. Silver, A
Advanced glycation end product concentrations in follicular fluid of women undergoing IVF/ICSI with a GnRH agonist protocol  Qi Yao, Yuanjiao Liang, Yong.
Intra-cycle fluctuations of anti-Müllerian hormone in normal women with a regular cycle: a re-analysis  Annelies Overbeek, Frank J. Broekmans, Wouter.
Janet Kwee, M. D. , Roel Schats, M. D. , Ph. D. , Joseph McDonnell, M
No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH  George Griesinger, Daniel B. Shapiro, Efstratios.
Anti-Müllerian hormone for the assessment of ovarian response in GnRH-antagonist- treated oocyte donors  Nikolaos P. Polyzos, Dominic Stoop, Christophe.
Patient-tailored ovarian stimulation for in vitro fertilization
A. La Marca, G. Sighinolfi, S. Giulini, M. Traglia, C. Argento, C
In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation 
Publication productivity in IVF in Europe, 1990–2006
Silke Klocke, Claudia Tappehorn, Georg Griesinger 
Isabel Pereira, M. D. , Kyra von Horn, M. D. , Marion Depenbusch, M. D
Factors affecting embryo viability and uterine receptivity: insights from an analysis of the UK registry data  Stephen A. Roberts, Mark Hann, Daniel R.
Ethnicity as a determinant of ovarian reserve: differences in ovarian aging between Spanish and Indian women  Carlos Iglesias, M.D., Manish Banker, M.D.,
Short follicular phase of stimulation following corifollitropin alfa or daily recombinant FSH treatment does not compromise clinical outcome: a retrospective.
Anti-Müllerian hormone as an independent predictor of twin versus singleton pregnancy in fresh cycles  Reshef Tal, David B. Seifer, Moisey Khanimov, Eliana.
Sherman Silber  Reproductive BioMedicine Online 
Why are reproductive cancers more common in nulliparous women?
Utility of age-specific serum anti-Müllerian hormone concentrations
Sarah McCredie, William Ledger, Christos A. Venetis 
Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine.
Corifollitropin alfa versus recombinant follicle-stimulating hormone: an individual patient data meta-analysis  Georg Griesinger, Robert Boostanfar, Keith.
Ovarian reserve determinations suggest new function of FMR1 (fragile X gene) in regulating ovarian ageing  Norbert Gleicher, Andrea Weghofer, David H.
Removal of unilateral endometriomas is associated with immediate and sustained reduction in ovarian reserve  Bulent Urman, Ebru Alper, Kayhan Yakin, Ozgur.
Randomized, controlled, open-label, non-inferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa  F. Olivennes, G. Trew,
Reproductive BioMedicine Online
Anti-Müllerian hormone for prediction of ovarian response in Chinese infertile women undergoing IVF/ICSI cycles: a prospective, multi-centre, observational.
John L. Yovich, Kevin N. Keane, Gayatri Borude, Satvinder S
Albert Hsu, M. D. , Margaret Arny, Ph. D. , Alexander B. Knee, M. S
Jyotsna Pundir, Sesh Kamal Sunkara, Tarek El-Toukhy, Yacoub Khalaf 
Myotonic dystrophy type 1 and PGD: ovarian stimulation response and correlation analysis between ovarian reserve and genotype  C. Dechanet, C. Castelli,
Follicular flushing in natural cycle IVF does not affect the luteal phase – a prospective controlled study  M. von Wolff, A. Kohl Schwartz, P. Stute,
Prospective study into the value of the automated Elecsys antimüllerian hormone assay for the assessment of the ovarian growing follicle pool  Richard.
Dehydroepiandrostendione sulphate and prediction of live birth after IVF in young women with low anti-Müllerian hormone concentration  Miro Šimun Alebić,
Michael J. Levy, William Ledger, Efstratios M. Kolibianakis, Pieta C
LH concentrations do not correlate with pregnancy in rFSH/GnRH antagonist cycles  Kevin Doody, Paul Devroey, Keith Gordon, Han Witjes, Bernadette Mannaerts 
Does ovarian stimulation regimen affect IVF outcome
GnRH antagonist pre-treatment: one centre's experience for IVF–ICSI cycle scheduling  Veronique Viardot-Foucault, Sadhana Nadarajah, Weng Kit Lye, Heng.
Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis.
A. La Marca, S. M. Nelson, G. Sighinolfi, M. Manno, E. Baraldi, L
Is parental consanguinity associated with reduced ovarian reserve?
Factors related to successful ovulation induction in patients with WHO group II anovulatory infertility  C.M. Howles, V. Alam, D. Tredway, R. Homburg,
Predictive value of ovarian reserve markers in smoking and non-smoking women undergoing IVF  Thomas Freour, Lionel Dessolle, Miguel Jean, Damien Masson,
Ovarian reserve screening before contraception?
Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH  Basil C. Tarlatzis,
The significance of the number of CGG repeats and autoantibodies in premature ovarian failure  Cem Fıçıcıoglu, Gazi Yildirim, Rukset Attar, Banu Kumbak,
Diminished intrafollicular estradiol levels in in vitro fertilization cycles from women with reduced ovarian response to recombinant human follicle-stimulating.
Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol  Georg Griesinger, M.D., Anja Dawson, M.D., Askan Schultze-Mosgau,
Reproductive BioMedicine Online
Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.
Intensified ovarian stimulation in a GnRH antagonist protocol with agonist triggering: a prospective, clinical feasibility study  Georg Griesinger, Henriette.
Cem Fiçicioǧlu, M. D. , Tayfun Kutlu, M. D. , Elif Baglam, M. D
M. Franz, J. Ott, A. Watrelot, L. Küssel, H. Husslein 
Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.
A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three- dimensional ultrasound determinants of ovarian reserve in the prediction.
Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era?  Antonio La Marca, Martina Capuzzo  Reproductive.
Presentation transcript:

Ovarian response to 150 µg corifollitropin alfa in a GnRH-antagonist multiple-dose protocol: a prospective cohort study  Tamara Lerman, Marion Depenbusch, Askan Schultze-Mosgau, Soeren von Otte, Markus Scheinhardt, Inke Koenig, Axel Kamischke, Milan Macek, Arne Schwennicke, Sabine Segerer, Georg Griesinger  Reproductive BioMedicine Online  Volume 34, Issue 5, Pages 534-540 (May 2017) DOI: 10.1016/j.rbmo.2017.02.012 Copyright © 2017 Terms and Conditions

Figure 1 Box and whisker plots of ovarian response by quartiles of woman's age, cycle length, AFC, AMH and FSH on cycle day 2 or 3. Values are median (lines), 25th to 75th percentiles (boxes) and 10th to 90th percentiles (whiskers). Percentiles are for age: 25th 30 years, 50th 34 years and 75th 36 years; cycle length: 25th 27 days, 50th 28 days and 75th 29 days; AFC: 25th 9, 50th 12 and 75th 16; AMH 25th 0.81 µg/l, 50th 1.61 µg/l and 75th: 2.95 µg/l; FSH: 25th: 6.15 IU/l, 50th 7.36 IU/l and 75th 9.04 IU/l. AFC = antral follicle count; AMH = anti-Müllerian hormone. Reproductive BioMedicine Online 2017 34, 534-540DOI: (10.1016/j.rbmo.2017.02.012) Copyright © 2017 Terms and Conditions

Figure 2 Receiver operator characteristic curves for low and high ovarian response (CI = confidence interval; ROCauc = area-under-the-receiver-operator-characteristic-curve). Reproductive BioMedicine Online 2017 34, 534-540DOI: (10.1016/j.rbmo.2017.02.012) Copyright © 2017 Terms and Conditions